Terms: = Endocrine gland cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1
204 results:
1. Activation of endogenous retroviruses and induction of viral mimicry by mek1/2 inhibition in pancreatic cancer.
Cortesi A; Gandolfi F; Arco F; Di Chiaro P; Valli E; Polletti S; Noberini R; Gualdrini F; Attanasio S; Citron F; Ho IL; Shah R; Yen EY; Spinella MC; Ronzoni S; Rodighiero S; Mitro N; Bonaldi T; Ghisletti S; Monticelli S; Viale A; Diaferia GR; Natoli G
Sci Adv; 2024 Mar; 10(13):eadk5386. PubMed ID: 38536927
[TBL] [Abstract] [Full Text] [Related]
2. The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies.
Hicks HM; Nassar VL; Lund J; Rose MM; Schweppe RE
Cancer Biol Ther; 2024 Dec; 25(1):2332000. PubMed ID: 38521968
[TBL] [Abstract] [Full Text] [Related]
3. AKT-independent signaling in PIK3CA-mutant thyroid cancer mediates resistance to dual SRC and mek1/2 inhibition.
Rose MM; Nassar KW; Sharma V; Schweppe RE
Med Oncol; 2023 Sep; 40(10):299. PubMed ID: 37713162
[TBL] [Abstract] [Full Text] [Related]
4. Cytomorphologic, immunophenotypical and molecular features of pancreatic acinar cell carcinoma.
Sun T; Gilani S; Jain D; Cai G
Diagn Cytopathol; 2023 Nov; 51(11):674-683. PubMed ID: 37469257
[TBL] [Abstract] [Full Text] [Related]
5. Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2.
Hicks HM; Pozdeyev N; Sams SB; Pugazhenthi U; Bales ES; Hofmann MC; McKenna LR; Schweppe RE
Mol Cancer Res; 2023 Sep; 21(9):867-880. PubMed ID: 37219859
[TBL] [Abstract] [Full Text] [Related]
6. The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer.
Entrialgo-Cadierno R; Cueto-Ureña C; Welch C; Feliu I; Macaya I; Vera L; Morales X; Michelina SV; Scaparone P; Lopez I; Darbo E; Erice O; Vallejo A; Moreno H; Goñi-Salaverri A; Lara-Astiaso D; Halberg N; Cortes-Dominguez I; Guruceaga E; Ambrogio C; Lecanda F; Vicent S
Mol Cancer; 2023 May; 22(1):86. PubMed ID: 37210549
[TBL] [Abstract] [Full Text] [Related]
7. Mass Spectrometry-Based Proteomics of Epithelial Ovarian cancers: A Clinical Perspective.
Qian L; Sun R; Xue Z; Guo T
Mol Cell Proteomics; 2023 Jul; 22(7):100578. PubMed ID: 37209814
[TBL] [Abstract] [Full Text] [Related]
8. The WNK1-ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib.
Sánchez-Fdez A; Matilla-Almazán S; Montero JC; Del Carmen S; Abad M; García-Alonso S; Bhattacharya S; Calar K; de la Puente P; Ocaña A; Pandiella A; Esparís-Ogando A
Clin Transl Med; 2023 Apr; 13(4):e1217. PubMed ID: 37029785
[TBL] [Abstract] [Full Text] [Related]
9. Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications.
Zhao Z; Li X; Wang F; Xu Y; Liu S; Han Q; Yang Z; Huang W; Yin Z; Liu Q; Tan H; Ma T; Si S; Huang J; Yuan H; Li W; Liu R
Cancer Med; 2023 May; 12(10):11672-11685. PubMed ID: 36999792
[TBL] [Abstract] [Full Text] [Related]
10. MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition.
Silvis MR; Silva D; Rohweder R; Schuman S; Gudipaty S; Truong A; Yap J; Affolter K; McMahon M; Kinsey C
J Exp Med; 2023 Mar; 220(3):. PubMed ID: 36719686
[TBL] [Abstract] [Full Text] [Related]
11. Increased endogenous PKG I activity attenuates EGF-induced proliferation and migration of epithelial ovarian cancer via the MAPK/ERK pathway.
Lan T; Li Y; Wang Y; Wang ZC; Mu CY; Tao AB; Gong JL; Zhou Y; Xu H; Li SB; Gu B; Ma P; Luo L
Cell Death Dis; 2023 Jan; 14(1):39. PubMed ID: 36653376
[TBL] [Abstract] [Full Text] [Related]
12. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic cancer Growth.
Erice O; Narayanan S; Feliu I; Entrialgo-Cadierno R; Malinova A; Vicentini C; Guruceaga E; Delfino P; Trajkovic-Arsic M; Moreno H; Valencia K; Blanco E; Macaya I; Öhlund D; Khatri P; Lecanda F; Scarpa A; Siveke JT; Corbo V; Ponz-Sarvise M; Vicent S
Clin Cancer Res; 2023 Mar; 29(6):1137-1154. PubMed ID: 36607777
[TBL] [Abstract] [Full Text] [Related]
13. Role of RAS signaling in ovarian cancer.
Therachiyil L; Anand A; Azmi A; Bhat A; Korashy HM; Uddin S
F1000Res; 2022; 11():1253. PubMed ID: 36451660
[TBL] [Abstract] [Full Text] [Related]
14. NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian cancers to MEK Inhibition.
Llaurado Fernandez M; Hijmans EM; Gennissen AMC; Wong NKY; Li S; Wisman GBA; Hamilton A; Hoenisch J; Dawson A; Lee CH; Bittner M; Kim H; DiMattia GE; Lok CAR; Lieftink C; Beijersbergen RL; de Jong S; Carey MS; Bernards R; Berns K
Mol Cancer Ther; 2022 Dec; 21(12):1862-1874. PubMed ID: 36198031
[TBL] [Abstract] [Full Text] [Related]
15. Robotic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: Analysis of surgical outcomes and long-term prognosis in a high-volume center.
Zhang XP; Xu S; Zhao ZM; Liu Q; Zhao GD; Hu MG; Tan XL; Liu R
Hepatobiliary Pancreat Dis Int; 2023 Apr; 22(2):140-146. PubMed ID: 36171169
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic Value, Immune Signature, and Molecular Mechanisms of the PHLDA Family in Pancreatic Adenocarcinoma.
Duan Y; Du Y; Gu Z; Zheng X; Wang C
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142223
[TBL] [Abstract] [Full Text] [Related]
17. Protein expression profiling identifies a prognostic model for ovarian cancer.
Xiong L; Tan J; Feng Y; Wang D; Liu X; Feng Y; Li S
BMC Womens Health; 2022 Jul; 22(1):292. PubMed ID: 35840928
[TBL] [Abstract] [Full Text] [Related]
18. Novel Therapeutics for Advanced Differentiated Thyroid cancer.
Lieberman L; Worden F
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):367-378. PubMed ID: 35662446
[TBL] [Abstract] [Full Text] [Related]
19. KIF22 Promotes Development of Pancreatic cancer by Regulating the MEK/ERK/P21 Signaling Axis.
Zhang R; Ma L; Wei Y; Wei K; Song T; Du Z; Feng Z
Biomed Res Int; 2022; 2022():6000925. PubMed ID: 35578724
[TBL] [Abstract] [Full Text] [Related]
20. Rare Ovarian cancer's First Positive Trial.
Cancer Discov; 2022 Apr; 12(4):879. PubMed ID: 35373274
[TBL] [Abstract] [Full Text] [Related]
[Next]